Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines (Q39781903)

14 September 2017

title

Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines (English)

1 reference

14 September 2017

1 reference

Charles S Dietrich

1

1 reference

14 September 2017

Victoria L Greenberg

2

1 reference

14 September 2017

Christopher P DeSimone

3

1 reference

14 September 2017

Susan C Modesitt

4

1 reference

14 September 2017

John R van Nagell

5

1 reference

14 September 2017

Rolf Craven

6

1 reference

14 September 2017

Stephen G Zimmer

7

1 reference

14 September 2017

language of work or name

English

0 references

publication date

28 October 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

116

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

126-130

1 reference

14 September 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

The fundamental role of epigenetic events in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylases and cancer: causes and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors as new cancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors in cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Validating survivin as a cancer therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

A p34(cdc2) survival checkpoint in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Microtubules, microtubule-interfering agents and apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Control of apoptosis and mitotic spindle checkpoint by survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Cancer gene therapy using a survivin mutant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Inhibition of melanoma tumor growth in vivo by survivin targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2009.09.039

10.1016/J.YGYNO.2009.09.039

7 January 2021

Identifiers

DOI

1 reference

release_xdjk566aqvhmzo72thrlpmznk4

14 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xdjk566aqvhmzo72thrlpmznk4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference